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Abstract 
Uterine cancer is the most common gynecologic malignancy in the United States with 
almost 62,000 cases expected in 2019. In general, treatment consists of primary surgery possibly 
followed by adjuvant radiation and/or chemotherapy. However, in cases with cervical 
involvement or when the patient is a non-surgical candidate, neoadjuvant treatment can be 
employed; specifically, neoadjuvant radiation with or without brachytherapy and/or 
chemotherapy. There have not been any large-scale studies looking at the addition of 
brachytherapy to external beam radiation in the neoadjuvant setting and whether or not its 
addition improves outcomes.   
In order to analyze this, the National Cancer Database was used to study women 
diagnosed with uterine cancer who were treated with neoadjuvant radiation with or without 
brachytherapy followed by hysterectomy. Univariate and multivariate cox regression survival 
analysis was done to look at overall survival (OS) between the group that received brachytherapy 
and the group that did not. Logistic regression was performed to analyze the association between 
the use of brachytherapy and negative margins upon surgical resection. Both cox regression 
analysis and logistic regression analysis were done for the entire cohort and for each histological 
subtype. 
 
 
 
There were 1009 women treated with neoadjuvant radiation followed by external beam, 
the majority of whom did not receive brachytherapy (n=640, 63.4%). Women who did receive 
brachytherapy were more likely to be stage II (p<0.001), and were less likely to have been 
treated at a community cancer center (p=0.045).  They were also less likely to have received a 
radical hysterectomy (p=0.009). The addition of brachytherapy was not associated with 
improved OS on univariate or multivariate analysis (HR=0.831, p=0.073; HR=0.868, p=0.179, 
respectively). This relationship remained across all histologies (all p>0.05). In addition, the use 
of brachytherapy was not associated with margin status on surgical resection in univariate or 
multivariate analysis (both p>0.05).  
The addition of brachytherapy to external beam radiation in the neoadjuvant setting did 
not affect survival in this cohort of uterine cancer patients. However, its use was associated with 
decreased utilization of radical hysterectomies, which is an important clinical finding as radical 
hysterectomies can be much more morbid than total hysterectomies. 
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BACKGROUND  
Literature Review  
Endometrial cancer is the most common gynecologic malignancy in the United 
States, and the fourth most common malignancy in women ("SEER Cancer State Facts: 
Uterine Cancer"). With the prevalence of major risk factors for uterine cancer increasing, 
including diabetes and obesity, the medical community has seen an increase in the incidence 
of uterine cancer, up from 40,100 patients diagnosed in 2008 to 61,880 expected in 2019 
(Corzo, Barrientos Santillan, Westin, & Ramirez, 2018; Jemal et al., 2008; "Key Statistics for 
Endometrial Cancer" 2019).  
Treatment guidelines for uterine cancer consist of multiple modalities depending on 
stage. The general treatment paradigm is primary surgery possibly followed by adjuvant 
therapy, though this is dependent on a patient’s ability to undergo a surgical procedure. 
Adjuvant therapy can consist of external beam radiation, chemotherapy, vaginal cuff 
brachytherapy, or a combination of these. Patients with early-stage disease are treated with 
hysterectomy followed by adjuvant radiotherapy only if adverse risk factors are present (most 
often vaginal cuff brachytherapy). Those with later stage disease may have hysterectomies 
with adjuvant therapy or chemoradiation alone depending on risk factors and suitability for 
surgery ("NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms").  
Locally advanced uterine cancer with cervical and/or parametrial extension comprises 
less than 10-15% of all endometrial cancer cases (Ahmad et al., 1989; Vargo et al., 2014). In 
part due to its low incidence, there is not a consensus on how to best treat these patients. The 
National Comprehensive Cancer Network (NCCN) details multiple approaches as 
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appropriate ("NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms"). For 
patients who are surgical candidates, either radical or total hysterectomy followed by 
adjuvant therapy or neoadjuvant (preoperative) radiation followed by total hysterectomy are 
suitable approaches. Oftentimes, radical hysterectomies are required for patients with 
cervical or parametrial involvement, as these include removal of the upper 1/3 of the vagina 
and parametrium in addition to the uterus and cervix. This is in contrast to a total 
hysterectomy, where only the uterus and cervix are removed. For those who are not able to 
undergo immediate surgery, either radiation or chemotherapy followed by surgery if they are 
rendered an operable candidate is acceptable. Neoadjuvant radiation is a category 2B 
recommendation by the NCCN, or based on “lower-level evidence,” in part due to the lack of 
studies looking at its effectiveness.  
Neoadjuvant (preoperative) therapy is frequently employed in patients who are obese 
or have other comorbidities that make a radical hysterectomy difficult, as total 
hysterectomies are shorter surgeries with fewer complications and risks than a radical 
hysterectomy (Shukla et al., 2011). Neoadjuvant radiation therapy can also be used to 
increase the likelihood of negative margins on surgical resection (Boisen et al., 2017). Pre-
operative radiation therapy consists of external beam radiation with or without brachytherapy 
(or intracavitary radiation). The use of brachytherapy as an adjunct to external beam radiation 
has not been adequately studied. Most studies examining the use of neoadjuvant radiation 
have been small retrospective case series, and have included only included patients who 
received brachytherapy (Boisen et al., 2017; Iheagwara et al., 2019; Vargo et al., 2014). 
However, the NCCN states that one “could consider adding” brachytherapy to neoadjuvant 
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radiation ("NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms"), and there 
have been no large-scale studies showing whether or not the addition of brachytherapy 
improves outcomes in these patients. 
This proposal is to study survival differences between patients treated with different 
neoadjuvant modalities for non-metastatic endometrial cancer. Specifically, this study will 
look at patterns of care and survival for patients treated with neoadjuvant radiation with or 
without brachytherapy. In addition, it will look at surgical margins and evaluate whether the 
use of brachytherapy improves the odds of having a negative surgical margin at time of 
hysterectomy. 
Public Health Significance 
It is still unknown as to whether or not patients who have uterine cancer being treated 
with neoadjuvant radiation should receive intracavitary radiotherapy. Neoadjuvant treatment 
is not widely utilized; however, it is used for patients with cervical involvement as well as 
those who are not candidates for immediate surgery. While cervical involvement of uterine 
cancer without occult lymph node involvement is rare, and only comprises 10-15% of all 
endometrial cancer cases, with approximately 62,000 uterine cancer cases total per year in 
the United States alone this is still a large population of women. In addition, due to the link 
between obesity, metabolic syndrome, and endometrial cancer, it is not uncommon for 
women to be ineligible for immediate surgery upon diagnosis (Shaw, Farris, McNeil, & 
Friedenreich, 2016). It is important to understand how to best treat this disease to improve 
survival for all of these women.  
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Hypothesis, Research Question, Specific Aims or Objectives 
As cervical involvement of uterine cancer is rare, and the use of neoadjuvant radiation 
even rarer, the use of a national database is a reasonable approach to maximize the number of 
cases. The research question that this proposal aims to answer is whether the use of 
brachytherapy in neoadjuvant radiation improves overall survival (OS) and/or margin status. 
In order to do so, the patterns of care and outcomes for all patients in the NCDB who 
received neoadjuvant radiation will be discussed. Then, the difference between patients who 
received neoadjuvant brachytherapy and those who did not will be analyzed. Finally, whether 
the use of brachytherapy in neoadjuvant radiation has an impact on margin status will be 
assessed.  
 
Objective 1: To describe the patterns of neoadjuvant radiation treatment, including 
sequencing with surgery and/or chemotherapy, and the use of brachytherapy, for uterine 
carcinomas treated with hysterectomy. 
 
Objective 2: To assess for differences in survival between patients who received neoadjuvant 
external beam and those who received neoadjuvant external beam plus brachytherapy for 
uterine carcinoma. 
 
Objective 3: To assess for differences in margin status for patients who received neoadjuvant 
external beam and those who received neoadjuvant external beam plus brachytherapy. 
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METHODS 
Study Design 
This is a retrospective study using a nationally available database, the National 
Cancer Database (NCDB).  
Study Subjects 
Women between ages 18 and 100 who were diagnosed with endometrial cancer and 
whose information is available in the NCDB were included. Participants were eligible for 
analysis if their disease characteristics were available (histology, stage), treatment 
characteristics were available (treatment sequence, radiation information and use of 
brachytherapy, chemotherapy information), and if they had available follow-up information. 
Participants who received neoadjuvant radiation followed by hysterectomy were analyzed. 
To eliminate death due to surgical complications, patients were excluded if they died within 
30 days of surgery. In addition, participants with more than one cancer diagnosis, carcinoma-
in-situ, or diagnosis at time of autopsy were excluded from analysis.  
Data Collection 
The NCDB is a joint program of the Commission on Cancer (CoC) of the American 
College of Surgeons and the American Cancer Society. The NCDB collects data from more 
than 1,5000 Commission-accredited cancer programs in the United States and Puerto Rico, 
which comprises approximately 70% of all new cancer diagnosis. Data is collected at each 
individual accredited institution and then submitted to the NCDB using nationally 
standardized data items and coding definitions.  
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Data Analysis 
All variables were decoded per NCDB guidelines, and all patients treated between 
2004 and 2014 were queried for analysis. First, the database was filtered to include only 
patients who received neoadjuvant radiation. Patients were then deemed eligible if they had a 
confirmed malignant uterine carcinoma and were between the ages of 18 and 100. Patients 
with benign disease, in-situ disease, or sarcomas were excluded. In addition, patients with 
missing vital status, those who died within 30 days of surgery, or who had fewer than 30 
days of follow-up were excluded.  
Next, patients with stage I-III disease were included in the cohort for analysis. AJCC 
clinical staging was used as the analysis is looking at the effect of neoadjuvant treatment, so 
clinical staging was deemed the most appropriate. Clinical stage was unavailable in 186 
patients, so pathologic stage was used. The cohort was then filtered to only those who were 
treated with both neoadjuvant radiation therapy followed by surgery as part of treatment. 
Specifically, all patients must have received a hysterectomy as part of their surgical 
management.  Those with a subtotal resection or exenteration were excluded. Patients who 
received either neoadjuvant external beam or external beam plus brachytherapy were 
included, while patients receiving brachytherapy only were excluded (Figure 1).  
After obtaining only subjects who fulfilled all inclusion and exclusion criteria, 
patients were categorized by whether or not they received brachytherapy as a part of their 
neoadjuvant treatment course. Demographics and disease characteristics between groups 
were compared. Chi-square analysis was used to compare all variables except age and tumor 
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size, for which independent T-test analysis was done. Survival was compared initially using 
Kaplan-Meier log rank tests.  
Univariate cox regression survival analysis was performed to analyze variables that 
could significantly affect OS. Multivariate cox regression survival analysis was then 
completed to control for confounding variables. Variables that could be associated with both 
the exposure variable of interest (the use of brachytherapy) and the outcome (OS) that were 
not deemed to be in the causal pathway between the two were considered for inclusion in the 
model (Dunkler, Plischke, Leffondre, & Heinze, 2014). A backwards stepwise selection 
algorithm was used for the multivariate cox regression model. The variables were eligible for 
inclusion in the multivariate cox regression if their significance level from the univariate 
analysis was <0.25. Variables continued to be eligible for the model if their significance level 
remained <0.05. For categorical variables with more than two options, if any significance 
value for the variable was <0.05 they remained in the model. Variables with subjects per 
variable of less than 20 were excluded from analysis (Green, 1991). The use of 
brachytherapy remained in the model regardless of significance value as this was the variable 
of interest. In the event of co-linearity between variables in the multivariate model, the 
variable that is deemed to be more likely causal of the event of interest (OS) will be included.  
A stratified analysis was then done for each histological sub-type to assess for innate 
biological differences. The histologies were broken down as follows: grade 1-2 endometrioid 
endometrial cancer was designated low-grade endometrioid disease, grade 3 endometrioid 
endometrial cancer was designated high-grade endometrioid disease, and all other histologies 
(serous cell, clear cell, and mixed histologies) were designated non-endometrioid histologies. 
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Univariate and multivariate cox regression survival analysis were performed. The same 
backwards stepwise algorithm was employed for each multivariate analysis with the same 
inclusion and exclusion significance and subject per variable criteria. Models were run 
separately for each analysis, allowing for different variables to be significant in each model. 
Another univariate and multivariate cox regression survival analysis was done for only 
patients with stage II disease, as these are the ones most often treated with neoadjuvant 
radiation.  
In addition, binary univariate and multivariate logistic regression was performed to 
assess for whether or not neoadjuvant brachytherapy improved odds of negative margins at 
time of surgical resection. Only patients with known margin status were included in this 
analysis. The multivariate model was again built using a backwards stepwise algorithm with 
significance levels of <0.25 to enter the model and <0.05 required to remain in the model. In 
the event of co-linearity between variables in the multivariate model, the variable that is 
deemed to be more likely causal of the event of interest (margin status) was included. The 
logistic regression was also repeated after stratifying by histological subtypes, low-grade 
endometrioid, high-grade endometrioid, and non-endometrioid histologies. 
Human Subjects Considerations  
Per the University of Texas Health Science Center at Houston Committee for the 
Protection of Human Subjects Office, this project did not qualify as human subject research 
as it is a de-identified database.  
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JOURNAL ARTICLE 
Title of Journal Article: The use of neoadjuvant brachytherapy in endometrial cancer: 
an NCDB analysis 
Name of Journal Proposed for Article Submission: Brachytherapy 
  
Introduction 
Endometrial cancer is the most common gynecologic malignancy in the United 
States, and the fourth most common malignancy in women ("SEER Cancer State Facts: 
Uterine Cancer"). With the prevalence of major risk factors for uterine cancer increasing, 
including diabetes and obesity, the medical community has seen an increase in the incidence 
of uterine cancer, up from 40,100 patients diagnosed in 2008 to 61,880 expected in 2019 
(Corzo et al., 2018; Jemal et al., 2008; "Key Statistics for Endometrial Cancer" 2019). 
Treatment guidelines for uterine cancer consist of multiple modalities depending on 
extent of the tumor burden. Patients with early-stage disease are treated with surgery and 
adjuvant radiotherapy (most often vaginal cuff brachytherapy), while those with later stage 
disease may have hysterectomies with adjuvant therapy or chemoradiation alone ("NCCN 
Clinical Practice Guidelines in Oncology: Uterine Neoplasms"). Adjuvant therapy, or 
treatment after primary surgery, can consist of external beam radiation, chemotherapy, 
brachytherapy, or a combination of these.   
There are occasionally indications for neoadjuvant treatment. These include, though 
are not limited to; stage II disease (or uterine cancer with cervical involvement), 
comorbidities that make surgery difficult, or bulky disease where the surgeon is concerned 
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about their ability to fully remove the tumor with negative margins (Shukla et al., 2011). Pre-
operative therapy can consist of radiation alone (which itself can be external beam and/or 
intracavitary radiation), concurrent chemoradiation, or systemic therapy alone. The use of 
brachytherapy as an adjunct to external beam in neoadjuvant radiation has not been 
adequately studied. Most studies examining the use of neoadjuvant radiation have been small 
retrospective series that have only included patients who received brachytherapy (Boisen et 
al., 2017; Iheagwara et al., 2019; Vargo et al., 2014). However, the NCCN is not clear on this 
issue and states that one “could consider adding” brachytherapy to neoadjuvant radiation to 
reduce the chance of positive margins ("NCCN Clinical Practice Guidelines in Oncology: 
Uterine Neoplasms"), and there have been no large-scale studies showing whether or not the 
addition of brachytherapy improves outcomes in these patients.  
This analysis utilized the National Cancer Database (NCDB) in order to better 
understand the utility of neoadjuvant brachytherapy in treating uterine cancer, and to 
examine whether its use increased survival or the odds of negative surgical margins. The 
NCDB is a joint program of the Commission on Cancer (CoC) of the American College of 
Surgeons and the American Cancer Society. It captures approximately 70% of all new cancer 
diagnosis in the United States, and is a hospital-based registry. 
Materials/Methods: 
We queried the NCDB for all women treated for uterine cancer between 2004 and 
2014. First, the database was filtered to include only patients who received neoadjuvant 
radiation. Patients were then deemed eligible if they had a confirmed uterine carcinoma and 
were between the ages of 18 and 100. Patients with benign disease, in situ disease, or 
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sarcomas were excluded. In addition, patients with missing vital status, those who died 
within 30 days of surgery, or who had less than 30 days of follow-up were excluded.  
Next, patients with stage I-III disease were included in the cohort for analysis. AJCC clinical 
staging was used as we are looking at the effect of neoadjuvant treatment, so clinical staging 
was deemed the most appropriate. Clinical stage was unavailable in 186 patients, so 
pathologic stage was used. The cohort was then filtered to only those who were treated with 
both neoadjuvant radiation therapy followed by surgery as part of treatment. Specifically, all 
patients must have received a hysterectomy as part of their surgical management.  Those with 
a subtotal resection or exenteration were excluded. Patients who received either neoadjuvant 
external beam or external beam plus brachytherapy were included, while patients receiving 
brachytherapy only were excluded (Figure 1).  
 Patients were separated into groups depending on whether or not they received 
brachytherapy as a part of their neoadjuvant treatment. Demographics and disease 
characteristics between groups were compared. Chi-square analysis was used to compare all 
variables except age and tumor size, for which independent T-test analysis was done. 
Univariate cox regression analysis was performed to assess for disease and treatment 
variables that had an effect on overall survival (OS). Multivariate cox regression was then 
done to control for confounding variables. A backwards stepwise algorithm was used with a 
significance level of <0.25 from the univariate analysis required to enter into the model, and 
<0.05 to stay in the model. This did not apply for the use of brachytherapy as it was the main 
exposure variable of interest. Univariate and multivariate analysis was repeated for each 
histological subtype separately in order to analyze the effect of brachytherapy on different 
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histologies. The histologies were broken down as follows: grade 1-2 endometrioid 
endometrial cancer was designated low-grade endometrioid disease, grade 3 endometrioid 
endometrial cancer was designated high-grade endometrioid disease, and all other histologies 
(serous cell, clear cell, and mixed histologies) were grouped as non-endometrioid histologies. 
In addition, a univariate and multivariate survival analysis was done limited to only stage II 
patients, as these are the patients who are most often treated with neoadjuvant radiation.  
 Binary logistic regression was performed to assess whether or not the use of 
brachytherapy or any other variable had an impact on margin status. Only patients with 
known margin status were included. Multivariate logistic regression was also done to control 
for confounding variables.  
Results:  
 After querying the NCDB and applying all inclusion and exclusion criteria, 1009 
women were eligible for analysis. Of these, 640 women received external beam radiation 
only for their disease, while 369 received neoadjuvant external beam and brachytherapy. 
Mean age was 62 years old, and the majority of patients were non-Hispanic white (n=776, 
76.9%). Almost all patients were insured (n=937, 92.9%), and had good functional status 
with Charleson-Deyo score less than 2 (n=946, 93.8%). Median follow-up time was 62.4 
months (95%CI 57.9-66.9 months) for the entire cohort. 
 There were considerably fewer women treated with brachytherapy at community 
cancer programs, with only 17% of patients treated at these facilities receiving brachytherapy 
(p=0.045). This is compared to comprehensive community cancer programs, academic or 
research programs, or integrated network cancer centers, where 34%, 39%, and 37% of their 
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patients received brachytherapy respectively (see Table 1). There were no differences in the 
percentage of women who received brachytherapy as a part of their neoadjuvant treatment 
across race/ethnicities, insurance status, Charleson-Deyo score, or histology. Significantly 
more patients with stage II disease received brachytherapy compared to those with stage I or 
III disease (p<0.001). Women were less likely to receive a modified radical or extended 
hysterectomy after the addition of brachytherapy to their radiation treatment (p=0.009). 
There was no difference in the percentage of women who received neoadjuvant or adjuvant 
chemotherapy between the external beam radiation only and external beam radiation plus 
brachytherapy groups (22% and 21%, respectively, p=0.056). However, there was a 
significant difference in the type of chemotherapy these women received. For women who 
were treated with neoadjuvant chemotherapy, those who received external beam radiation 
only were significantly more likely to be treated with multi-agent chemotherapy (n=54, 
38.6%) as compared to those who received external beam radiation with brachytherapy 
(n=16, 20.8%; p=0.001). Median survival for patients treated with brachytherapy was 106.8 
months compared to 88.6 months for those without (p=0.073, Figure 2). 
 On univariate analysis non-Hispanic black women had significantly worse OS than 
other race and ethnic groups (Table 2). The type of surgical procedure had no effect on OS, 
though residual tumor after surgical resection was associated with worse survival (HR 2.250, 
p<0.001). Stage III patients did significantly worse than stage I or II patients (HR=1.900, 
p<0.001), and high-grade endometrioid adenocarcinoma or serous, clear cell, or mixed 
histologies were associated worse OS than those with low-grade endometrioid carcinoma 
(HR=2.010, p<0.001; HR=2.227, p<0.001, respectively).  
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 The addition of brachytherapy did not affect OS on univariate analysis (HR=0.831, 
p=0.073). The presence of any chemotherapy was significantly associated with survival in 
that those who received chemotherapy had worse OS than those who did not (HR=1.220, 
p=0.046). Specifically, patients who received adjuvant chemotherapy after surgery did 
significantly worse than other groups (HR =1.444, p=0.015).  
 To control for confounding variables, a multivariate analysis was done (Table 3). 
Age, Charleson-Deyo score, histology, stage, the presence of any chemotherapy, and the 
addition of brachytherapy were the final variables included in this model. After controlling 
for these variables, the addition of brachytherapy was still not associated with OS 
(HR=0.868, p=0.179). Increasing age, the presence of comorbidities, high-risk histologies 
(high-grade endometrioid and non-endometrioid), higher stage, and unknown status of 
chemotherapy delivery remained significantly associated with OS. Patients with unknown 
chemotherapy status did better than those who did not receive any (HR=0.367, p=0.016), 
however there was no difference between patients who received chemotherapy and those 
who did not (HR=1.128, p=0.285) after controlling for other variables. Again, patients with 
low-grade endometrioid cancer had significantly improved OS compared to those with high-
grade endometrioid disease (HR=1.600, p<0.001) and non-endometrioid histologies 
(HR=1.801, p<0.001).  
 Sub-analyses were done across each histological subtype. The use of brachytherapy 
was associated with improved OS in univariate analysis in non-endometrioid histologies only 
(HR=0.659, p=0.017, Appendix A). However, this association disappeared on multivariate 
analysis, and brachytherapy was not associated with OS for any histology (all p>0.05). 
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Increasing age was the only variable to remain significantly associated with worse OS in 
each multivariate model (all p≤0.001, Appendix B). In both low- and high-grade 
endometrioid histologies, stage III disease was associated with worse OS (both p<0.05), 
though stage was not a significant factor in non-endometrioid patients. Caucasian patients did 
better than non-Hispanic black patients with non-endometrioid histologies (HR=0.585, 
p=0.005). In the sub-analysis limited to only stage II patients, brachytherapy again did not 
affect OS in either univariate or multivariate analysis (Appendix C).  
 Binary logistic regression was done to assess for the effect of brachytherapy and other 
variables on margin status. The addition of brachytherapy was not associated with margin 
status (p=0.237, Table 4). However, increased stage and high-risk histologies were both 
associated with decreased odds of negative margins on surgical resection. On multivariate 
logistic regression, stage II and stage III disease remained associated with decreased odds of 
negative margins on resection (OR=0.284, p=0.012; OR=0.254, p=0.006, respectively). 
Histology was no longer associated with negative margins once stage and the use of 
chemotherapy were accounted for. The use of neoadjuvant chemotherapy did not alter the 
odds of negative margins compared to no chemotherapy (OR=0.821, p=0.593). After 
stratifying the analysis by histology, the use of brachytherapy did not affect the odds of the 
patient having negative margins on resection for any histology (all p>0.05, Appendix D).  
Discussion:  
 This analysis of NCDB data examined whether or not the addition of brachytherapy 
to neoadjuvant radiation treatment for endometrial cancer was associated with an 
improvement in OS. Per NCCN guidelines, neoadjuvant radiation can be employed for 
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uterine cancer in cases where there is gross evidence of cervical involvement (which is 
known as stage II disease), or when patients are not initially surgical candidates ("NCCN 
Clinical Practice Guidelines in Oncology: Uterine Neoplasms"). There are not strict 
guidelines on when or how brachytherapy should be employed for neoadjuvant radiation. 
Some reports have detailed the practice of only adding brachytherapy when there was 
evidence of gross cervical disease, and otherwise have just utilized external beam radiation 
(Reisinger, Staros, Feld, Mohiuddin, & Lewis, 1992). Oftentimes, neoadjuvant brachytherapy 
is added to external beam for stage II disease in every case (Boisen et al., 2017; Iheagwara et 
al., 2019; Shukla et al., 2011). However, there have been no randomized trials looking at 
whether or not the addition of brachytherapy improves outcomes for these patients; whether 
they have stage II disease and have gross cervical involvement, or if they are being treated 
with radiation as the first-course of treatment in hopes to prepare them for surgery. This is 
likely due to the fact that neoadjuvant radiation is rarely utilized in endometrial cancer.  
 In this retrospective analysis, the addition of brachytherapy to neoadjuvant radiation 
for the treatment of endometrial cancer was not significantly associated with OS. This result 
was seen both when analyzing the entire cohort and after stratifying by histology. A previous 
study looking at adjuvant radiation for stage II patients was able to show a benefit in disease-
free survival when treating with external beam plus brachytherapy compared to 
brachytherapy alone; however, they did not show any improvement in OS. Importantly, they 
did not compare external beam alone plus brachytherapy (Ozgul et al., 2018).  
 Previous studies have reported that neoadjuvant radiation can improve the chance of 
negative margins on surgical resection, particularly in high-risk histologies (Iheagwara et al., 
 
 
17 
 
2019). However, to our knowledge there have not been any large-scale studies that looked at 
whether or not the addition of brachytherapy to external beam radiation improved these 
chances. This analysis indicates that the addition of brachytherapy does not improve the odds 
of negative margins on surgical resection when compared to external beam radiation alone. 
Again, this remained constant across all histological sub-types.  
 Notably however, the addition of brachytherapy was associated with a significant 
decrease in the utilization of radical hysterectomies in this cohort. This is important because 
radical hysterectomies have increased incidence of major complications when compared to 
total hysterectomies (Mariani, Webb, Keeney, Calori, & Podratz, 2001). One of the main 
reasons neoadjuvant radiation is utilized for endometrial cancer is that it can debulk the 
initial disease allowing surgeons to remove the tumor with a total hysterectomy instead of a 
radical hysterectomy, thus hoping to reduce surgical complications (Boisen et al., 2017; 
Iheagwara et al., 2019). If the addition of brachytherapy can allow a surgeon to perform a 
total hysterectomy instead of a radical hysterectomy, this can render its addition an important 
part of the treatment paradigm. Due to its retrospective nature it is not possible in this study 
to look at whether or not patients with who were treated with brachytherapy were candidates 
for total hysterectomy after their external beam radiation but before their brachytherapy 
treatment. We also cannot look at the toxicity profile of neoadjuvant treatment with 
brachytherapy followed by total hysterectomy as compared to neoadjuvant external beam 
only followed by radical hysterectomy. Both of these are important and should be 
investigated in a prospective nature.  
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 There are significant limitations to the study. Most notably, as it is a retrospective 
database study, we cannot examine the reasons as to why the physician chose whether or not 
to add brachytherapy to the radiation treatment. They may have been concerned for local 
recurrence based on physical exam, image findings, or other factors that we cannot examine 
in this study. Additionally, some of the physicians may have chosen to exclude 
brachytherapy based on patient factors such as inability to tolerate treatment, but these cannot 
be determined either. Another important limitation of this study is that we can only examine 
OS, and cannot look at either local control or disease-free survival. Radiation is utilized for 
local control, and unfortunately, we cannot examine whether or not the addition of 
brachytherapy helped to increase local control in this cohort. Lastly, we cannot look at 
toxicity or quality of life information. As most uterine cancer patients have a good prognosis, 
long-term toxicities are very important to consider when deciding on treatment plans.  
 While there are limitations, this study does have many advantages. First, it is the only 
study we know of that looks directly at whether or not the addition of brachytherapy to 
external beam radiation in the neoadjuvant setting improves survival or the odds of negative 
margins in endometrial cancer patients. Additionally, it has a very large cohort for a rare 
treatment, as neoadjuvant radiation is not commonly employed for endometrial cancer. The 
ability to stratify the analysis by histological type is also an advantage of this study, as there 
are innate biological differences between histologies that are important when looking at 
prognostic factors. A prospective study looking at the addition of brachytherapy to 
neoadjuvant radiation treatment for uterine cancer is recommended to fully examine how we 
should be treating these patients.   
 
 
19 
 
Table 1:  Patient demographics and treatment characteristics  
 
 No Brachytherapy Brachytherapy  
  
Number of 
Patients (n) (%) 
Number of 
Patients (n) (%) p-value 
Total (n) 640 63% 369 37%  
Mean age at diagnosis (yrs) 62.9 11.8 61.1 11.8 0.016 
Facility Type     0.045 
Community Cancer Program 29 5% 6 2%  
Comprehensive Community Cancer Program 251 40% 130 37%  
Academic/Research Program 269 43% 174 49%  
Integrated Network Program 72 12% 42 12%  
Unknown 19 3% 17 5%  
Race     0.633 
Non-Hispanic Black  90 14% 43 12%  
Hispanic 38 76% 19 79%  
Other 28 6% 15 5%  
Non-Hispanic White 484 4% 292 4%  
Insurance Status     0.696 
Un-insured 40 6% 19 5%  
Insured 591 92% 346 94%  
Unknown 9 1% 4 1%  
Charleson-Deyo Score     0.315 
0 444 69% 266 72%  
1 152 24% 84 23%  
2 35 5% 18 5%  
3 9 1% 1 0%  
Stage     <0.001 
I 168 26% 61 17%  
II 207 32% 162 44%  
III 265 41% 146 40%  
Histology/Grade     0.517 
Grade 1-2 endometrioid 317 50% 169 46%  
Grade 3 endometrioid 142 22% 89 24%  
Non-endometrioid histologies 181 28% 111 30%  
Surgical Margins     0.298 
Negative 524 82% 316 86%  
Positive 48 8% 21 6%  
Unknown 68 11% 32 9%  
Surgical Procedure      0.009 
Total Hysterectomy 541 85% 333 90%  
Modified radical or extended hysterectomy 56 9% 14 4%  
Hysterectomy, NOS 43 7% 22 6%  
Received Chemotherapy     0.068 
No 332 52% 173 47%  
Yes 290 45% 191 52%  
Unknown 18 3% 5 1%  
Chemotherapy Sequence     0.056 
None 332 52% 173 47%  
Neoadjuvant 140 22% 77 21%  
Adjuvant 77 12% 42 11%  
Other/Unknown 91 14% 77 21%  
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Table 2:  Univariate cox regression survival analysis comparing neoadjuvant radiation 
with and without brachytherapy  
  HR LL 95% CI UL 95% CI p-value 
Mean age at diagnosis (yrs) 1.04 1.032 1.049 <0.001 
Facility Type     
Community Cancer Program 1   ref 
Comprehensive Community Cancer Program 1.027 0.605 1.744 0.922 
Academic/Research Program 0.982 0.580 1.664 0.946 
Integrated Network Program 1.234 0.696 2.187 0.472 
Race     
Non-Hispanic Black  1   ref 
Hispanic 0.649 0.500 0.842 0.001 
Other 0.403 0.231 0.705 0.001 
Non-Hispanic White 0.441 0.239 0.815 0.009 
Insurance Status     
Un-insured 1   ref 
Insured 1.583 0.960 2.610 0.072 
Unknown --- --- --- --- 
Charleson-Deyo Score     
0 1   ref 
1 1.068 0.847 1.348 0.577 
2 1.494 1.025 2.178 0.037 
3 --- --- --- --- 
Stage     
I 1   ref 
II 1.045 0.788 1.387 0.758 
III 1.900 1.458 2.475 <0.001 
Histology/Grade     
Grade 1-2 endometrioid 1   ref 
Grade 3 endometrioid 2.010 1.574 2.566 <0.001 
Non-endometrioid histologies 2.227 1.774 2.796 <0.001 
Surgical Procedure      
Total hysterectomy 1   ref 
Modified radical or extended hysterectomy 1.074 0.735 1.568 0.713 
Hysterectomy, NOS 0.898 0.603 1.337 0.595 
Surgical Margins     
No residual tumor 1   ref 
Residual 2.250 1.631 3.104 <0.001 
Unknown 1.306 0.961 1.773 0.088 
Radiation     
External Beam  1   ref 
External Beam + Brachytherapy 0.831 0.679 1.018 0.073 
Received Chemotherapy     
No 1   ref 
Yes 1.045 0.834 1.309 0.701 
Unknown 0.353 0.155 0.803 0.013 
Chemotherapy Sequence     
None 1   ref 
Neoadjuvant 1.110 0.855 1.442 0.434 
Adjuvant 1.444 1.073 1.943 0.015 
Other/Unknown 1.100 0.843 1.436 0.483 
*--- indicates that there were not enough subjects per variable to be included in analysis (Green, 1991)  
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Table 3:  Multivariate cox regression survival analysis comparing neoadjuvant 
radiation with and without brachytherapy 
 HR LL 95% CI UL 95% CI p-value 
Age  1.040 1.031 1.050 <0.001 
Charleson-Deyo Score     
0 1   ref 
1 1.049 0.831 1.324 0.688 
2 1.607 1.093 2.363 0.016 
Stage     
I 1   ref 
II 1.073 0.798 1.444 0.639 
III 1.751 1.315 2.330 <0.001 
Histology/Grade     
Grade 1-2 endometrioid 1   ref 
Grade 3 endometrioid 1.600 1.243 2.060 <0.001 
Non-endometrioid histologies 1.801 1.417 2.288 <0.001 
Radiation     
External Beam  1   ref 
External Beam + Brachytherapy 0.898 0.705 1.067 0.179 
Received Chemotherapy     
No 1   ref 
Yes 1.128 0.904 1.408 0.285 
Unknown 0.367 0.161 0.832 0.016 
*--- indicates that there were not enough subjects per variable to be included in analysis (Green, 1991) 
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Table 4: Univariate and Multivariate binary logistic regression analyzing factors 
associated with negative margin status on surgical resection  
 Univariate Multivariate 
  OR p-value OR p-value 
Facility Type     
Community Cancer Program 1 ref --- --- 
Comprehensive Community Cancer Program 1.528 0.511 --- --- 
Academic/Research Program 1.258 0.718 --- --- 
Integrated Network Program 0.867 0.835 --- --- 
Race     
Non-Hispanic Black  1 ref --- --- 
Hispanic 0.932 0.900 --- --- 
Other 1.255 0.737 --- --- 
Non-Hispanic White 1.276 0.484 --- --- 
Stage     
I 1 ref 1 ref 
II 0.290 0.013 0.284 0.012 
III 0.189 0.001 0.254 0.006 
Histology/Grade     
Grade 1-2 endometrioid 1 ref 1 ref 
Grade 3 endometrioid 0.465 0.017 0.533 0.056 
Non-endometrioid histologies 0.448 0.007 0.597 0.100 
Surgical Procedure      
Total hysterectomy 1 ref --- --- 
Modified radical or extended hysterectomy 0.464 0.210 --- --- 
Hysterectomy, NOS 0.489 0.211 --- --- 
Radiation     
External Beam  1 ref 1 ref 
External Beam + Brachytherapy 1.378 0.237 1.642 0.076 
Chemotherapy Sequence     
None 1 ref 1 ref 
Neoadjuvant 0.676 0.278 0.821 0.593 
Adjuvant 0.246 0.000 0.335 0.003 
Other/Unknown 0.370 0.003 0.472 0.036 
*--- indicates that there were not enough subjects per variable to be included in analysis (Green, 1991) 
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Figure 1:  Cohort Selection 
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Figure 2: Kaplan-Meier comparing survival in patients treated with neoadjuvant 
radiation with or without brachytherapy, p=0.073 
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CONCLUSION 
 In this retrospective NCDB analysis, the use of brachytherapy in neoadjuvant 
radiation for uterine cancer was not significantly associated with OS or with increased odds 
of negative margins on surgical resection when compared to external beam radiation alone. 
These findings remained constant across all histological sub-types. Notably however, the 
addition of brachytherapy was associated with a significant decrease in the utilization of 
radical hysterectomies, a much more morbid surgery than a total hysterectomy. If the 
addition of brachytherapy can allow a surgeon to perform a total hysterectomy instead of a 
radical hysterectomy, this can render its addition an important part of the treatment paradigm. 
Due to its retrospective nature it is not possible in this study to look at factors leading 
physicians towards choosing to add brachytherapy to external beam, or toxicities. However, 
this is one of the largest studies of patients undergoing neoadjuvant radiation for uterine 
cancer to date.  We also cannot look at the toxicity profile of neoadjuvant external beam with 
brachytherapy followed by total hysterectomy as compared to neoadjuvant external beam 
only followed by radical hysterectomy. While neoadjuvant radiation for uterine cancer is 
rare, it is becoming increasingly important to examine all treatment paradigms with the 
increasing incidence of uterine cancer. A prospective study looking at the addition of 
brachytherapy to neoadjuvant radiation treatment for uterine cancer is recommended to fully 
examine how we should be treating these patients.  
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APPENDICES 
Appendix A:  Univariate cox regression survival analysis stratified by histology  
Low-grade endometrioid endometrial cancer 
  No. cases HR LL 95% CI UL 95% CI p-value 
Total (n) 486     
Mean age at diagnosis (yrs)  1.035 1.021 1.050 <0.001 
Facility Type      
Community Cancer Program 172 1   ref 
Comprehensive Community Cancer Program 216 1.454 0.525 4.023 0.471 
Academic/Research Program 50 1.467 0.534 4.031 0.457 
Integrated Network Program 172 2.458 0.849 7.117 0.097 
Race      
Non-Hispanic Black  39 1     ref  
Hispanic 37 0.540 0.184 1.583 0.261 
Other 21 0.721 0.226 2.301 0.581 
Non-Hispanic White 389 1.246 0.654 2.372 0.504 
Insurance Status      
Un-insured 33 1     ref  
Insured 6 --- --- --- --- 
Unknown 447 0.926 0.471 1.821 0.825 
Charleson-Deyo Score      
0 340 1     ref  
1 117 1.115 0.753 1.653 0.587 
2 25 2.412 1.372 4.238 0.002 
3 4 --- --- --- --- 
Stage      
I 132 1     ref  
II 196 1.054 0.684 1.623 0.812 
III 158 1.771 1.154 2.717 0.009 
Surgical Procedure       
Total Hysterectomy 427 1     ref  
Modified Radical or extended hyst 28 1.108 0.563 2.178 0.766 
Hysterectomy, NOS 31 0.661 0.309 1.415 0.287 
Surgical Margins      
No residual tumor 426 1     ref  
Residual 22 1.344 0.657 2.749 0.417 
Unknown 38 1.253 0.721 2.179 0.423 
Radiation      
External Beam  317 1     ref  
External Beam + Brachytherapy 169 1.004 0.718 1.403 0.982 
Received Chemotherapy      
No 286 1     ref  
Yes 190 1.094 0.780 1.536 0.602 
Unknown 10 --- --- --- --- 
Chemotherapy Sequence      
None 286 1     ref  
Neoadjuvant 106 0.935 0.589 1.483 0.775 
Adjuvant 38 1.275 0.712 2.286 0.414 
Other/Unknown 56 1.035 0.637 1.681 0.891 
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High-grade endometrioid endometrial cancer 
  No. cases HR LL 95% CI UL 95% CI p-value 
Total (n) 231     
Mean age at diagnosis (yrs)  1.025 1.008 1.042 0.003 
Facility Type      
Community Cancer Program 8 --- --- --- --- 
Comprehensive Community Cancer Program 101 1   ref 
Academic/Research Program 98 0.938 0.639 1.378 0.745 
Integrated Network Program 22 0.386 0.154 0.965 0.042 
Race      
Non-Hispanic Black  35 1   ref 
Hispanic 10 --- --- --- --- 
Other 8 --- --- --- --- 
Non-Hispanic White 178 0.785 0.486 1.269 0.323 
Insurance Status      
Un-insured 11 --- --- --- --- 
Insured 4 --- --- --- --- 
Unknown 216 --- --- --- --- 
Charleson-Deyo Score      
0 168 1   ref 
1 49 1.051 0.665 1.660 0.832 
2 12 --- --- --- --- 
3 2 --- --- --- --- 
Stage      
I 40 1   ref 
II 82 0.966 0.523 1.785 0.913 
III 109 2.215 1.262 3.885 0.006 
Surgical Procedure       
Total Hysterectomy 197 1   ref 
Modified Radical or extended hyst 20 1.186 0.618 2.278 0.607 
Hysterectomy, NOS 14 --- --- --- --- 
Surgical Margins      
No residual tumor 180 1   ref 
Residual 20 2.929 1.681 5.103 0.000 
Unknown 31 1.463 0.878 2.439 0.144 
Radiation      
External Beam  142 1   ref 
External Beam + Brachytherapy 89 0.753 0.514 1.104 0.146 
Received Chemotherapy      
No 113 1   ref 
Yes 116 1.146 0.792 1.658 0.469 
Unknown 2 --- --- --- --- 
Chemotherapy Sequence      
None 113 1   ref 
Neoadjuvant 51 0.928 0.560 1.537 0.771 
Adjuvant 26 1.412 0.783 2.548 0.252 
Other/Unknown 41 1.158 0.712 1.882 0.555 
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Non-endometrioid endometrial cancer 
  No. cases HR LL 95% CI UL 95% CI p-value 
Total (n) 292     
Mean age at diagnosis (yrs)  1.045 1.030 1.061 <0.001 
Facility Type      
Community Cancer Program 7 --- --- --- --- 
Comprehensive Community Cancer Program 108 1   ref 
Academic/Research Program 129 1.030 0.717 1.481 0.873 
Integrated Network Program 42 1.473 0.919 2.361 0.108 
Race      
Non-Hispanic Black  59 1   ref 
Hispanic 10 --- --- --- --- 
Other 14 --- --- --- --- 
Non-Hispanic White 209 0.570 0.392 0.828 0.003 
Insurance Status      
Un-insured 15 --- --- --- --- 
Insured 3 --- --- --- --- 
Unknown 274 --- --- --- --- 
Charleson-Deyo Score      
0 202 1   ref 
1 70 1.078 0.742 1.565 0.694 
2 16 --- --- --- --- 
3 4 --- --- --- --- 
Stage      
I 57 1   ref 
II 91 1.068 0.666 1.713 0.784 
III 144 1.339 0.867 2.067 0.188 
Surgical Procedure       
Total Hysterectomy 250 1   ref 
Modified Radical or extended hyst 22 0.830 0.436 1.579 0.569 
Hysterectomy, NOS 20 0.962 0.520 1.781 0.902 
Surgical Margins      
No residual tumor 234 1   ref 
Residual 27 2.010 1.235 3.270 0.005 
Unknown 31 1.030 0.601 1.763 0.916 
Radiation      
External Beam  181 1   ref 
External Beam + Brachytherapy 111 0.659 0.468 0.928 0.017 
Received Chemotherapy      
No 106 1   ref 
Yes 175 1.021 0.731 1.426 0.904 
Unknown 11 --- --- --- --- 
Chemotherapy Sequence      
None 106 1   ref 
Neoadjuvant 60 1.224 0.801 1.870 0.350 
Adjuvant 55 1.064 0.679 1.667 0.787 
Other/Unknown 71 0.789 0.508 1.226 0.291 
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Appendix B:  Multivariate cox regression survival analysis stratified by histology  
 
Low-grade 
endometrioid 
High-grade 
endometrioid Non-endometrioid 
  HR p-value HR p-value HR p-value 
Mean age at diagnosis (yrs) 1.037 <0.001 1.030 0.001 1.043 <0.001 
Race       
Non-Hispanic Black  --- --- --- --- 1 ref 
Hispanic --- --- --- --- ---  
Other --- --- --- --- ---  
Non-Hispanic White --- --- --- --- 0.585 0.005 
Charleson-Deyo Score       
0 1 ref --- --- --- --- 
1 1.034 0.867 --- --- --- --- 
2 2.641 0.001 --- --- --- --- 
3 --- --- --- --- --- --- 
Stage       
I 1 ref 1 ref --- --- 
II 1.074 0.754 0.958 0.895 --- --- 
III 1.787 0.010 1.981 0.021 --- --- 
Radiation       
External Beam  1 ref 1 ref 1 ref 
External Beam + Brachytherapy 1.136 0.469 0.789 0.237 0.806 0.241 
 
Appendix C:  Univariate and multivariate cox regression survival analysis for stage II 
patients only  
Univariate cox regression analysis for stage II disease  
  No. cases HR LL 95% CI UL 95% CI p-value 
Total (n) 369     
Mean age at diagnosis (yrs)  1.047 1.031 1.063 <0.001 
Facility Type      
Community Cancer Program 10 --- --- --- --- 
Comprehensive Community Cancer Program 120 1   ref 
Academic/Research Program 167 0.908 0.612 1.348 0.633 
Integrated Network Program 51 1.137 0.678 1.907 0.626 
Race      
Non-Hispanic Black  53 1   ref 
Hispanic 18 --- --- --- --- 
Other 15 --- --- --- --- 
Non-Hispanic White 283 0.555 0.359 0.858 0.008 
Insurance Status      
Un-insured 19 --- --- --- --- 
Insured 3 --- --- --- --- 
Unknown 347 --- --- --- --- 
Charleson-Deyo Score      
0 254 1   ref 
1 83 1.357 0.904 2.036 0.141 
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2 30 1.698 0.978 2.947 0.060 
3 2 --- --- --- --- 
Histology       
Grade 1-2 endometrioid 196 1   ref 
Grade 3 endometrioid 82 1.575 1.017 2.441 0.042 
Non-endometrioid histologies 91 2.300 1.548 3.419 0.000 
Surgical Procedure       
Total Hysterectomy 324 1   ref 
Modified Radical or extended hyst 25 1.353 0.709 2.583 0.359 
Hysterectomy, NOS 20 0.211 0.052 0.854 0.029 
Surgical Margins      
No residual tumor 310 1   ref 
Residual 25 1.948 1.071 3.545 0.029 
Unknown 34 1.354 0.788 2.327 0.273 
Radiation      
External Beam  207 1   ref 
External Beam + Brachytherapy 162 0.777 0.549 1.102 0.157 
Received Chemotherapy      
No 213 1   ref 
Yes 150 1.423 1.006 2.014 0.046 
Unknown 6 --- --- --- --- 
Chemotherapy Sequence      
None 213 1   ref 
Neoadjuvant 76 1.264 0.787 2.031 0.333 
Adjuvant 36 2.476 1.519 4.038 0.000 
Other/Unknown 44 0.916 0.524 1.601 0.758 
 
Multivariate cox regression analysis for stage II disease 
  HR LL 95% CI UL 95% CI p-value 
Mean age at diagnosis (yrs) 1.044 1.028 1.060 <0.001 
Histology      
Grade 1-2 endometrioid 1   ref 
Grade 3 endometrioid 1.262 0.807 1.973 0.308 
Non-endometrioid histologies 2.134 1.428 3.189 <0.001 
Radiation     
External Beam  1   ref 
External Beam + Brachytherapy 0.773 0.543 1.100 0.152 
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Appendix D:  Univariate and multivariate binary logistic regression stratified by histology   
Low-grade endometrioid endometrial cancer 
 Univariate Multivariate 
  OR p-value OR p-value 
Facility Type     
Community Cancer Program 1 ref --- --- 
Comprehensive Community Cancer Program 1.467 0.728 --- --- 
Academic/Research Program 1.253 0.835 --- --- 
Integrated Network Program 1.022 0.985 --- --- 
Stage     
I 1 ref --- --- 
II 0.432 0.209 --- --- 
III 0.341 0.113 --- --- 
Surgical Procedure      
Total hysterectomy 1 ref --- --- 
Modified radical or extended hysterectomy 1.206 0.858 --- --- 
Hysterectomy, NOS 0.603 0.513 --- --- 
Radiation     
External Beam  1 ref 1 ref 
External Beam + Brachytherapy 1.153 0.762 1.281 0.605 
Chemotherapy Sequence     
None 1 ref 1 ref 
Neoadjuvant 0.401 0.108 0.400 0.108 
Adjuvant 0.264 0.063 0.264 0.063 
Other/Unknown 0.176 0.003 0.171 0.003 
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High-grade endometrioid endometrial cancer 
 Univariate Multivariate 
  OR p-value OR p-value 
Facility Type     
Community Cancer Program 1 ref --- --- 
Comprehensive Community Cancer Program 1.464 0.736 --- --- 
Academic/Research Program 1.175 0.886 --- --- 
Integrated Network Program 1.071 0.958 --- --- 
Race     
Non-Hispanic Black  1 ref --- --- 
Hispanic --- --- --- --- 
Other --- --- --- --- 
Non-Hispanic White 2.145 0.182 --- --- 
Stage     
I 1 ref 1 ref 
II 0.276 0.242 0.241 0.198 
III 0.160 0.083 0.148 0.072 
Radiation     
External Beam  1 ref 1 ref 
External Beam + Brachytherapy 2.192 0.145 2.327 0.121 
Chemotherapy Sequence     
None 1 ref --- --- 
Neoadjuvant 1.290 0.713 --- --- 
Adjuvant 0.613 0.492 --- --- 
Other/Unknown 0.542 0.306 --- --- 
*surgical procedure excluded due to low n 
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Non-endometrioid endometrial cancer 
 Univariate Multivariate 
  OR p-value OR p-value 
Facility Type     
Community Cancer Program 1 ref --- --- 
Comprehensive Community Cancer Program 1.917 0.569 --- --- 
Academic/Research Program 1.417 0.756 --- --- 
Integrated Network Program 0.778 0.830 --- --- 
Race     
Non-Hispanic Black  1 ref --- --- 
Hispanic 1.021 0.985 --- --- 
Other 1.404 0.764 --- --- 
Non-Hispanic White 1.129 0.807 --- --- 
Stage     
I 1 ref 1 ref 
II 0.147 0.073 0.133 0.060 
III 0.123 0.045 0.115 0.039 
Radiation     
External Beam  1 ref 1 ref 
External Beam + Brachytherapy 1.273 0.575 1.491 0.359 
Chemotherapy Sequence     
None 1 ref --- --- 
Neoadjuvant 0.800 0.739 --- --- 
Adjuvant 0.218 0.005 --- --- 
Other/Unknown 0.667 0.500 --- --- 
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